Jones T H, Darne J F, McGarrigle H H
University Department of Medicine, Northern General Hospital, Sheffield, UK.
Eur J Endocrinol. 1994 Aug;131(2):173-8. doi: 10.1530/eje.0.1310173.
When human chorionic gonadotrophin (hCG) is used to stimulate testosterone synthesis and release in males with hypogonadotrophic hypogonadism, it is administered two or three times weekly by intramuscular injection. We have compared the pharmacokinetics of a twice weekly standard dose of hCG (5000 U) given for the first week by intramuscular injection and in the second week by self-administered subcutaneous injection. The patients studied had Kallmann's syndrome, isolated idiopathic hypogonadotrophic hypogonadism or post-traumatic isolated hypogonadotrophic hypogonadism. Salivary testosterone was collected twice daily at 08.00 h and 20.00 h, and serum testosterone was collected after 0, 24 h, 72 h, 120 h and 168 h each week. The cumulated serum and salivary testosterone levels were comparable on both intramuscular and subcutaneous hCG. In normal males there is diurnal variation in testosterone, with peak serum levels in the morning falling to a nadir in the evening. The exact nature and controlling factors of this circadian rhythm have not been established. In four of the subjects, the twice weekly hCG injections, either subcutaneous or intramuscular, produced a regular testosterone diurnal rhythm. The other four patients had fluctuations in testosterone but with no strict diurnal pattern. This study provides evidence that the luteinizing hormone-like action of hCG is necessary to prime the circadian rhythm but only a single bolus of hCG is sufficient to induce the rhythm in the absence of endogenous gonadotrophin production. In conclusion, self-administered subcutaneous hCG is safe and produces comparable levels of serum and salivary testosterone to that administered by the intramuscular route. Moreover, it was very well accepted by the patients and was preferred to conventional treatments. Human hCG in some patients with hypogonadotrophic hypogonadism produces normal physiological changes in daily testosterone levels.
当使用人绒毛膜促性腺激素(hCG)刺激性腺功能减退性性腺功能减退男性的睾酮合成与释放时,通过肌肉注射每周给药两到三次。我们比较了第一周通过肌肉注射、第二周通过自我皮下注射给予的每周两次标准剂量hCG(5000 U)的药代动力学。所研究的患者患有卡尔曼综合征、特发性孤立性性腺功能减退性性腺功能减退或创伤后孤立性性腺功能减退性性腺功能减退。每天08:00和20:00收集唾液睾酮,每周在0、24小时、72小时、120小时和168小时后收集血清睾酮。肌肉注射和皮下注射hCG时累积的血清和唾液睾酮水平相当。在正常男性中,睾酮存在昼夜变化,血清水平峰值出现在早晨,傍晚降至最低点。这种昼夜节律的确切性质和控制因素尚未确定。在四名受试者中,每周两次的hCG注射,无论是皮下注射还是肌肉注射,都产生了规律的睾酮昼夜节律。其他四名患者的睾酮有波动,但没有严格的昼夜模式。这项研究提供了证据,表明hCG的促黄体生成素样作用对于启动昼夜节律是必要的,但在没有内源性促性腺激素产生的情况下,仅单次大剂量hCG就足以诱导该节律。总之,自我皮下注射hCG是安全的,并且产生的血清和唾液睾酮水平与肌肉注射相当。此外,患者对其接受度很高,比传统治疗更受青睐。在一些性腺功能减退性性腺功能减退患者中,人hCG可使每日睾酮水平产生正常的生理变化。